论文部分内容阅读
为探讨同种异基因Th2细胞移植是否可以减低移植物抗宿主病 (GVHD)的发生和保留移植物抗白血病 (GVL)效应的作用 ,在体外用rmIL 4 ,ConA和离子霉素把供鼠 (C5 7BL/ 6 H 2b)T细胞优势化诱导培养为Th2细胞 ,再把Th2细胞与供鼠骨髓细胞混合移植给红白血病受鼠模型(EL96 11H 2d)。结果表明 :未处理的对照组 ,受鼠平均存活时间为 (10 .6± 1 3)天 ,10只均死于白血病 ;环磷酰胺化疗组 ,小鼠平均存活 (18 7± 4 2 )天 ,10只小鼠最终均死于白血病 ;骨髓细胞和脾T淋巴细胞移植组 ,小鼠平均存活 (2 2 7± 7 4 )天 ,9/ 10只均死于GVHD ;骨髓细胞和Th2细胞移植组 ,3/ 10只在 2 8天内死于GVHD ,其余 7/ 10只无GVHD发生 ,白血病发病时间明显推迟 ,平均存活 (36 9± 10 8)天 ,在 5 0天时检查有 2只鼠无白血病证据。研究证明体外极向化诱导培养的Th2细胞移植可减低GVHD发生的同时保留了抗白血病的能力。
To investigate whether allogeneic Th2 cell transplantation can reduce the occurrence of graft-versus-host disease (GVHD) and preserve the effects of graft-versus-leukemia (GVL) effects, donor mice were treated with rmIL 4 , ConA and ionomycin in vitro ( C5 7BL/ 6 H 2b) T cells were induced by Th2 cells in a predominant manner. Th2 cells were then mixed with donor mouse bone marrow cells and transplanted into a mouse model of erythroleukemia (EL96 11H2d). The results showed that: In the untreated control group, the average survival time of the mice was (10 .6 ± 1 3) days, and 10 patients all died of leukemia; in the cyclophosphamide chemotherapy group, the mice survived (18 7 ± 4 2) days on average. , 10 mice eventually died of leukemia; bone marrow cells and spleen T lymphocyte transplantation group, mice survived an average of (2 2 7 ± 7 4) days, 9/10 died of GVHD; bone marrow cells and Th2 cell transplantation In the group, 3 out of 10 died of GVHD within 28 days, and the remaining 7/10 had no GVHD. The onset time of leukemia was significantly delayed. The average survival time was (36 9 +/- 10) days. At the time of 50 days, 2 rats were examined. Leukemia evidence. Studies have demonstrated that in vitro thyroid-induced Th2 cell transplantation can reduce the occurrence of GVHD while retaining the ability to resist leukemia.